Havenaar E C, Hoff R C, van den Eijnden D H, van Dijk W
Department of Medical Chemistry, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands.
Glycoconj J. 1998 Apr;15(4):389-95. doi: 10.1023/a:1006977903048.
Mice are frequently used in models for the study of immunological processes related to inflammation. Since it is known that the degree of fucosylation of human acute phase proteins (APPs) is altered as a consequence of an inflammatory response, we have undertaken this study to gain more insight into the fucosylation of acute phase proteins as it occurs in mouse liver. Mice carrying the cluster of the three genes encoding human alpha1-acid glycoprotein (AGP), one of the well known APPs, were used and the fucosylation of AGP was assessed. A complete absence of fucosylation on the transgenic human AGP was found, which is in sharp contrast to AGP in human serum, of which a major proportion is normally alpha3-fucosylated. Remarkably, a large proportion of mouse AGP did contain fucose residues. Fucosylation was also detected on another APP, mouse protease inhibitor (PI). Alpha3-fucosylation of the transgenic human AGP can be achieved in vitro, using an alpha3/4-fucosyltransferase (alpha3/4-FucT) isolated from human milk, showing that the glycoprotein is not intrinsically resistant to fucosylation. Upon subsequent measurement of the activities of the possible fucosyltransferases present in liver membranes of parent and transgenic mice, only an N-linked-core alpha6-FucT and no alpha2-, alpha3- or alpha4-FucT activity was detected. This indicates that fucose residues found on the mouse serum proteins AGP and PI, which are synthesized in the liver, are most probably in alpha6-linkage to the core chitobiosyl unit. Interestingly, both alpha6- and alpha3-FucT activity was detectable in human liver membranes. None of the above mentioned findings were influenced by the induction of an acute phase response by administration of bacterial lipopolysaccharide. This study shows that: (a) alpha6-FucT is probably a protein specific-glycosyltransferase, since mouse AGP, but not human AGP, may be used as an acceptor; (b) in contrast to human liver, mouse liver does not express any alpha3-FucT-activity, thereby making the mouse incapable of producing the Sialyl Lewis(x) epitope on APPs, which is an important part of the inflammatory reaction in humans. This last finding indicates that the mouse is not suitable as a model for the study of those phenomena related to inflammation in humans, in which glycosylation of acute phase proteins could play a significant role.
小鼠常用于与炎症相关的免疫过程研究模型。由于已知人类急性期蛋白(APPs)的岩藻糖基化程度会因炎症反应而改变,我们开展了这项研究,以更深入了解小鼠肝脏中急性期蛋白的岩藻糖基化情况。使用携带编码人类α1-酸性糖蛋白(AGP,一种著名的APP)的三个基因簇的小鼠,并评估AGP的岩藻糖基化。结果发现转基因人类AGP上完全没有岩藻糖基化,这与人类血清中的AGP形成鲜明对比,人类血清中的AGP大部分通常是α3-岩藻糖基化的。值得注意的是,很大一部分小鼠AGP确实含有岩藻糖残基。在另一种APP,即小鼠蛋白酶抑制剂(PI)上也检测到了岩藻糖基化。使用从人乳中分离的α3/4-岩藻糖基转移酶(α3/4-FucT),可在体外实现转基因人类AGP的α3-岩藻糖基化,这表明该糖蛋白并非本质上对岩藻糖基化有抗性。在随后测量亲本和转基因小鼠肝膜中可能存在的岩藻糖基转移酶的活性时,仅检测到N-连接核心α6-FucT活性,未检测到α2-、α3-或α4-FucT活性。这表明在肝脏中合成的小鼠血清蛋白AGP和PI上发现的岩藻糖残基很可能以α6-连接与核心壳二糖单元相连。有趣的是,在人肝膜中可检测到α6-和α3-FucT活性。上述所有发现均不受通过给予细菌脂多糖诱导急性期反应的影响。这项研究表明:(a)α6-FucT可能是一种蛋白质特异性糖基转移酶,因为小鼠AGP而非人类AGP可作为受体;(b)与人类肝脏不同,小鼠肝脏不表达任何α3-FucT活性,从而使小鼠无法在APPs上产生唾液酸化路易斯(x)表位,而这是人类炎症反应的重要组成部分。最后这一发现表明,小鼠不适宜作为研究与人类炎症相关现象的模型,在这些现象中急性期蛋白的糖基化可能起重要作用。